Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Localized prostate cancer: Effect of frailty and comorbidity on surgical contraindication

Key clinical point: This FRART-PC study found that the geriatric 8 screening (G8) scores and comorbidities have a significant effect on surgical contraindication in patients with localized prostate cancer. Frailty may play a key role in treatment selection in clinical practice.

Major finding: The G8 score in patients treated with robot-assisted radical prostatectomy (RARP) and radiotherapy (RT) eligible for surgery (RT-nonfrail) was significantly higher vs. those with RT ineligible for surgery because of frailty or comorbidity (RT-frail; 15 vs. 14; P less than .001). Presence of comorbidities (cerebrocardiovascular disease or chronic respiratory disease; odds ratio [OR], 12.0; P less than .001), age (OR, 1.18; P less than .001), and G8 score (OR, 0.72; P=.003) were significantly associated with the RT-frail group.

Study details: This FRART-PC study included 479 patients with localized prostate cancer who were divided into 2 groups: RARP (n=256) and RT-nonfrail (n=60), those with surgical indications, and RT-frail (n=163), those with surgical contraindication.

Disclosures: This study was supported by Japan Society for the Promotion of Science KAKENHI and a research grant from the 31th Japanese Society of Geriatric Urology. The authors declared no conflicts of interest.

Citation:

Kodama H et al. Urol Oncol. 2020 Jul 16. doi: 10.1016/j.urolonc.2020.06.019.